GP Healthcare Group is located in Jinan Pharma Valley Industrial Park,
High-tech District. It is an innovative technology-based private and high-tech
enterprise. The group was founded by School of Pharmaceutical Science of
Shandong University Prof. Fengyou Lu. Mr. Lu possesses 24 years of market
operating experience in pharmaceutical market in the Greater China region, and
has successfully run four foreign-funded enterprises and large private
enterprises. The main business scope of the Group includes bio-pharmaceutical R&D,
development and sales of medical informatization software, medical high-tech
introduction, production and sales of medical quality supplies, dietary
supplement, medicine, as well as agents and sales of medical equipment
supplies. There are 220 staff. Besides the Group had more than 10 international
and national patents, and its annual turnover nearly reaches RMB 1 billion.
Since its establishment in 2006, the Group’s marketing team has achieved 11 years of marketing history, with annual sales exceeding RMB 300 million. The marketing team specializes in the promotion of pharmaceutical medical devices and consumables, on behalf of the products: Xin Tai Lin, when the Fei Li Gan Ning capsules, gangliosides, surgical orthopedic supplies and other products. More than 50 in-service marketing staff and more than 2,000 agents. The marketing department, the Ministry of Commerce, the training department, and the customer service department are all well-equipped and have perfect functions. The scope of business covers more than 20 provinces across the country: Beijing, Shanghai, Zhejiang, Jiangsu, Shandong, Hebei, Henan, Anhui, Hunan, Hubei, Sichuan, Chongqing, Guangdong, Fujian, Liaoning, Heilongjiang, etc. Home hospitals cooperate.
In the past five years, the Group has established strategic partnerships with various universities in biomedicine in Toronto, Montreal, Boston, New York and Connecticut, and established a wide range of government resource management and business contacts. The relationship has been multi-level investment for more than 20 projects. In Toronto, Montreal, and New York, a total of more than RMB 50 million has been invested to screen world-class projects in the future biopharmaceutical industry.
Four major international projects have been introduced:
Canadian McGill University genetically-coated heart stents, Yale University Hepatitis B cure vaccine, Canada male infertility detection technology of Mount Sinai Hospital, and the United States Ma Wei stroke stroke clearance project. The global production bases for the four major projects will all be located in Jinan Hi-tech Zone. After the project has matured and matured, it will take five to seven years to build a world-class biopharmaceutical industrial park in Jinan Medicine Valley and Life Science City. The park plans to acquire 500 acres of land and gradually establish five multi-functional parks: biopharmaceutical incubators and Chinese Test Base Park; Pharmaceutical Logistics and Pharmaceutical Product Trade Complex Park; Innovative Pharmaceutical and Medical Devices, Consumables and Health Products Industrial Park; International Cardiovascular and Cerebrovascular Hospital and Elderly Rehabilitation Park; and Talent Training Base with University of Toronto, Tsinghua University and Shandong University - Pharmaceutical Business School Park.
the first “Sino-Canadian Biomedical & New Technology Cooperation Forum”
held on October 24, 2015 in Jinan, Shandong. The Group had academic exchanges
and cooperation with Yale University, University of Michigan; McGill
University, University of Toronto, McMaster University, Queen’s University,
Bethune Medical Development Association. With Shandong GP Healthcare Group as
the platform, they jointly established “Sino-North American Innovative Medical
Investment & Industry Alliance which introduces the world’s most advanced
biomedical technology to China, and promotes the rapid development of national
medical industry with science and technology innovation. The forum is held once
the next five years, Shandong GP Healthcare Group will be based in Shandong province
and expand market of North America, develop new technology from the innovation
top cooperation of the medical industry chain, introduce various world-class
projects, set up marketing management platform covering the whole Greater China
in the circulation agent market, and establish the specialized hospital chain
platform with leading technology, reasonable prices and efficient operating in
hospital terminal market.